DNA-mediated immunization in a transgenic mouse model of the hepatitis B surface antigen chronic carrier state
- PMID: 8901610
- PMCID: PMC38020
- DOI: 10.1073/pnas.93.22.12496
DNA-mediated immunization in a transgenic mouse model of the hepatitis B surface antigen chronic carrier state
Abstract
Transgenic mice expressing the sequences coding for the envelope proteins of the hepatitis B virus (HBV) in the liver have been used as a model of the HBV chronic carrier state. We evaluated the possibility of inducing a specific immune response to the viral envelope antigens and thus potentially controlling chronic HBV infection. Using HBV-specific DNA-mediated immunization in this transgenic model, we show that the immune response induced after a single intramuscular injection of DNA resulted in the complete clearance of circulating hepatitis B surface antigen and in the long-term control of transgene expression in hepatocytes. This response does not involve a detectable cytopathic effect in the liver. Adoptive transfer of fractionated primed spleen cells from DNA-immunized mice shows that T cells are responsible for the down-regulation of HBV mRNA in the liver of transgenic mice. To our knowledge, this is the first demonstration of a potential immunotherapeutic application of DNA-mediated immunization against an infectious disease and raises the possibility of designing more effective ways of treating HBV chronic carriers.
Similar articles
-
Regulation of hepatitis B virus mRNA expression in a hepatitis B surface antigen transgenic mouse model by IFN-gamma-secreting T cells after DNA-based immunization.J Immunol. 1998 Nov 15;161(10):5564-70. J Immunol. 1998. PMID: 9820533
-
Overcoming T cell tolerance to the hepatitis B virus surface antigen in hepatitis B virus-transgenic mice.J Immunol. 2001 Jan 15;166(2):1389-97. doi: 10.4049/jimmunol.166.2.1389. J Immunol. 2001. PMID: 11145724
-
Breaking tolerance leads to autoantibody production but not autoimmune liver disease in hepatitis B virus envelope transgenic mice.J Immunol. 1995 Mar 1;154(5):2504-15. J Immunol. 1995. PMID: 7868916
-
Hepatitis B virus immunopathogenesis.Annu Rev Immunol. 1995;13:29-60. doi: 10.1146/annurev.iy.13.040195.000333. Annu Rev Immunol. 1995. PMID: 7612225 Review.
-
Hepatitis B virus (HBV)-transgenic mice as an investigative tool to study immunopathology during HBV infection.Int J Exp Pathol. 1998 Oct;79(5):279-91. doi: 10.1046/j.1365-2613.1998.740406.x. Int J Exp Pathol. 1998. PMID: 10193311 Free PMC article. Review.
Cited by
-
How grim is hepatocellular carcinoma?Ann Med Surg (Lond). 2014 Jul 4;3(3):71-6. doi: 10.1016/j.amsu.2014.06.006. eCollection 2014 Sep. Ann Med Surg (Lond). 2014. PMID: 25568791 Free PMC article. Review.
-
Changes to the natural killer cell repertoire after therapeutic hepatitis B DNA vaccination.PLoS One. 2010 Jan 18;5(1):e8761. doi: 10.1371/journal.pone.0008761. PLoS One. 2010. PMID: 20090916 Free PMC article. Clinical Trial.
-
DNA immunization with fusion genes encoding different regions of hepatitis C virus E2 fused to the gene for hepatitis B surface antigen elicits immune responses to both HCV and HBV.World J Gastroenterol. 2002 Jun;8(3):505-10. doi: 10.3748/wjg.v8.i3.505. World J Gastroenterol. 2002. PMID: 12046080 Free PMC article.
-
Mechanism and therapeutic potential of DNA-based immunization against the envelope proteins of hepatitis B virus in normal and transgenic mice.Immunology. 2001 May;103(1):90-7. doi: 10.1046/j.1365-2567.2001.01202.x. Immunology. 2001. PMID: 11380696 Free PMC article.
-
Nucleic acid vaccines: A taboo broken and prospect for a hepatitis B virus cure.World J Gastroenterol. 2021 Nov 7;27(41):7005-7013. doi: 10.3748/wjg.v27.i41.7005. World J Gastroenterol. 2021. PMID: 34887624 Free PMC article.
References
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical